Abstract 311P
Background
Despite genetic testing (GT) and counselling (GC) being key in breast cancer (BC) risk assessment, GC uptake rates are low even among pts undergoing GT. A global survey was conducted among pts with BC to identify the gaps in the GC experience and to propose strategies to fill them.
Methods
A steering committee comprising of pts and pt advocates co-developed a 38-question survey, which was offered to pts in Argentina, Australia, Brazil, Egypt, India, Malaysia, Mexico, Russia and Taiwan in local languages, through social media. The questions pathway was dependent on response to prior questions. Chi-square test was used to assess significance between responses, if applicable.
Results
The final analysis set (FAS) included responses from 1176 respondents with a > 90% completion rate of survey questions. In the FAS, 737 (63%) respondents reported having undergone GT. Most respondents in the FAS (768/1061; 71%) rated their awareness level of GT/GC (before BC diagnosis) as between ‘very low’ to ‘moderate’. Among pts undergoing GT, 616 respondents responded to the question enquiring on the resources available to them to guide their GT experience, beyond their oncologist. These were the genetic counsellor (295/616; 48%), pt support groups (232/616; 38%) and websites (217/616; 35%). Among the 439 respondents who did not undergo GT, 174 (40%) were offered GT by their doctor but did not take it. The table shows the level of understanding of GC reimbursement eligibility among the respondents. Table: 311P
Question | Population | No. of respondents | Response [n (%)] | ||
Did you receive any GC?* | Yes | No | I don't know | ||
Tested | 737 | 327 (44) | 266 (36) | 86 (12) | |
Not tested | 439 | 31 (7) | 277 (63) | 46 (11) | |
Should you qualify, is the cost of GC for breast cancer reimbursed in your country? | FAS | 1176 | 302 (26) | 174 (15) | 372 (32) |
Tested | 737 | 325 (44) | 129 (18) | 283 (38) | |
Not tested | 439 | 82 (19) | 120 (27) | 237 (54) |
*Statistically significant difference (p<0.00001) between tested and not tested pts
.Conclusions
Most pts with BC are not offered GC, which significantly correlates with GT uptake. Since poor awareness of GC is a critical gap, improving GC services and pt education through pt advocates and online tools may increase GT rates, offering a more impactful GT experience for pts and their families.
Clinical trial identification
Editorial acknowledgement
Professional medical writing assistance was provided by Madhubrata Ghosh, PhD, of Ward6 Singapore Pte Ltd, Singapore and funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca UK Limited.
Funding
AstraZeneca International (AstraZeneca UK limited).
Disclosure
R. Kaur: Financial Interests, Personal, Advisory Board: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Research Grant: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Institutional, Other: Pfizer, Novartis, Roche; Financial Interests, Personal, Advisory Board, Honoraria: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Other, Congress participation, travel support, lectures: Pfizer, Novartis; Financial Interests, Personal, Training: Pfizer, Novartis; Financial Interests, Personal, Advisory Role: Pfizer, Novartis, Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Advisory Board, Congress participation, travel support, lectures: Roche; Financial Interests, Personal, Other, Congress participation, lectures: AstraZeneca; Financial Interests, Personal, Other: AstraZeneca. S.L. Powell: Financial Interests, Personal, Full or part-time Employment: Pink Hope; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca; Non-Financial Interests, Personal, Other, Travel support: AstraZeneca. M. Artigas: Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. I. Borovova: Financial Interests, Personal, Full or part-time Employment: Russian Association of Oncology Patients “ZDRAVSTVUY!”; Financial Interests, Personal, Advisory Board: Public Council under the Ministry of Health of the Russian Federation, Presidential Council for the Development of Civil Society and Human Rights, Public Council under Roszdravnadzor, Council for Social Welfare under the Government of the Russian Federation, AstraZeneca. P. Gadiya: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Role: AstraZeneca. A. Hsu: Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. L. Kidd: Financial Interests, Personal, Full or part-time Employment: Victorian Department of Education, Beaconsfield Primary School; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. D. Rosenfeld: Financial Interests, Personal, Advisory Board: AstraZeneca. M.M. Saeed: Financial Interests, Personal, Advisory Board: AstraZeneca. E. Scarelli: Financial Interests, Personal, Full or part-time Employment: OncoGuia Institute; Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Novartis, Roche, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca, Pfizer, Novartis, Roche, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Officer, Congress participation, lectures: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca, Pfizer, Roche, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Other, Congress participation, lectures: Pfizer, Roche, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Invited Speaker, Congress participation, lectures: Novartis; Financial Interests, Personal, Other: Novartis. M. Wahib: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca.
Resources from the same session
303P - Differential prognostic role of PDGFRA alterations in breast cancer subtypes
Presenter: Panagiotis Vlachostergios
Session: Poster session 02
304P - Generalizability of 313-SNP PRS for breast cancer risk in non-European ancestries
Presenter: Helen Shang
Session: Poster session 02
305P - Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
Presenter: Sora Kang
Session: Poster session 02
307P - Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline
Presenter: Xixuan Zhu
Session: Poster session 02
308P - Regression-based deep-learning predicts breast cancer recurrence risk score from pathology slides
Presenter: Omar El Nahhas
Session: Poster session 02
310P - Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
Presenter: Mitchell Elliott
Session: Poster session 02
312P - Prediction model of breast cancer patient’s neoadjuvant treatment outcome using breast cancer organoids cultured from core needle biopsies
Presenter: Dong Woo Lee
Session: Poster session 02
313P - Intrinsic subtypes in a cohort of early breast cancer patients
Presenter: Theresa Bracht
Session: Poster session 02